Neuron23 Announces Usage of Roche's Digital Biomarker and Device in Parkinson's Disease Clinical Trial
Portfolio Pulse from
Neuron23 is utilizing Roche's digital biomarker in its Phase 2 NEULARK trial for NEU-411, targeting early Parkinson's disease.
November 19, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Roche's digital biomarker is being used by Neuron23 in a Phase 2 trial for Parkinson's disease, highlighting Roche's role in advancing digital health solutions.
Roche's involvement in the NEULARK trial through its digital biomarker underscores its influence in the digital health space, potentially boosting its reputation and investor interest.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80